Total buying$00 buys
UTHR
UNITED THERAPEUTICS Corp
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 09/19 to 10/19.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$103M283 sells
Net open-market−$103MBuying minus selling
Active insiders2Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Oct 16, 2026
Open-market transaction mix · 283 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 105 | 0 | $0 | $37.1M | -$37.1M |
| Oct 2026 | 0 | 178 | 0 | $0 | $66.3M | -$66.3M |
Distinct insiders active
Reporting-owner CIKs by month · peak Oct 2026 (2)Sep 2026Oct 2026
Largest insider activity
By absolute net disclosed value · current transaction page- RA-$4.0M
- MA+$1.1M
UTHR transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
UTHRUNITED THERAPEUTICS Corp | Mahon Paul AEVP · GC | S · sale10b5-1 detectedSEC filing ↗ | -$145kView disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Mahon Paul AEVP · GC | M · exercise10b5-1 detectedSEC filing ↗ | $1.21MView disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Rothblatt Martine ACHAIR · CEO | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | $0View disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Rothblatt Martine ACHAIR · CEO | S · sale10b5-1 detectedSEC filing ↗ | -$21.8kView disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Rothblatt Martine ACHAIR · CEO | S · sale10b5-1 detectedSEC filing ↗ | -$261kView disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Rothblatt Martine ACHAIR · CEO | S · sale10b5-1 detectedSEC filing ↗ | -$261kView disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Rothblatt Martine ACHAIR · CEO | S · sale10b5-1 detectedSEC filing ↗ | -$217kView disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Rothblatt Martine ACHAIR · CEO | S · sale10b5-1 detectedSEC filing ↗ | -$478kView disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Rothblatt Martine ACHAIR · CEO | S · sale10b5-1 detectedSEC filing ↗ | -$1.04MView disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Rothblatt Martine ACHAIR · CEO | S · sale10b5-1 detectedSEC filing ↗ | -$1.08MView disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Rothblatt Martine ACHAIR · CEO | S · sale10b5-1 detectedSEC filing ↗ | -$283kView disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Rothblatt Martine ACHAIR · CEO | S · sale10b5-1 detectedSEC filing ↗ | -$606kView disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Rothblatt Martine ACHAIR · CEO | S · sale10b5-1 detectedSEC filing ↗ | -$340kView disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Rothblatt Martine ACHAIR · CEO | S · sale10b5-1 detectedSEC filing ↗ | -$214kView disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Rothblatt Martine ACHAIR · CEO | S · sale10b5-1 detectedSEC filing ↗ | -$128kView disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Rothblatt Martine ACHAIR · CEO | S · sale10b5-1 detectedSEC filing ↗ | -$21.2kView disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Rothblatt Martine ACHAIR · CEO | S · sale10b5-1 detectedSEC filing ↗ | -$63.7kView disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Rothblatt Martine ACHAIR · CEO | S · sale10b5-1 detectedSEC filing ↗ | -$84.8kView disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Rothblatt Martine ACHAIR · CEO | S · sale10b5-1 detectedSEC filing ↗ | -$21.0kView disclosure → | |
UTHRUNITED THERAPEUTICS Corp | Rothblatt Martine ACHAIR · CEO | M · exercise10b5-1 detectedSEC filing ↗ | $1.11MView disclosure → |
Filing-only signals
Deterministic matches in the selected period
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period325transactionstxns
- S · Open-market sells · dominant283 · 87%
- M · Option exercise42 · 13%
Activity by reported role
A joint filing can contribute to multiple rolesChief executive officer305
CHAIR305
EVP20
GC20
Reported Holdings After
Separated by insider, security, and ownership type
Rothblatt Martine ACommon Stock · Indirect · by Trust
324,443Oct 15, 2026
Mahon Paul ACommon Stock · Direct
45,172Oct 15, 2026
Rothblatt Martine AStock Option · Indirect · by Trust
223,910Oct 15, 2026
Mahon Paul AStock Option · Direct
30,940Oct 15, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redSep 19 → Oct 19
LessMore
UNITED THERAPEUTICS Corp Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at UNITED THERAPEUTICS Corp?
ROTHBLATT MARTINE A, MAHON PAUL A.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Rothblatt Martine A reported a sale on Oct 15, 2026 valued at $66.1k. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $103,547,823.93. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.